Aino Launonen
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study.
Journal: Journal of medical economics
Published: September 13, 2023
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Journal: Journal of medical economics
Published: September 07, 2023
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial.
Journal: PharmacoEconomics - open
Published: September 12, 2022
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 30, 2022
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial.
Journal: PharmacoEconomics - open
Published: May 18, 2022
Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies.
Journal: Oncology and therapy
Published: April 01, 2021
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Journal: Journal of managed care & specialty pharmacy
Published: February 15, 2021
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
Journal: Advances in therapy
Published: January 15, 2021
The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.
Journal: Journal of comparative effectiveness research
Published: October 05, 2020
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Journal: Haematologica
Published: May 03, 2020
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Journal: Haematologica
Published: October 14, 2018
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Journal: Annals of hematology
Published: August 26, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026